Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met on 17 January 2017 and has provided the Minister with the recommendations in respect of amendments to the Prescribed List. On considering these recommendations, the Minister would like to make the following amendments. - New products to be added to the Prescribed List
1.1 Linagliptin 5mg tablet (brand name Trajenta); linagliptin/metformin 2.5mg/850mg, 2.5mg/1000mg tablets (brand name Jentadueto) for the treatment of type 2 diabetes mellitus 1.2 Tretinoin 250mcg/gram with clindamycin 10mg/gram gel (brand name Treclin) for the treatment of acne 1.3 Insulin degludec 100 IU per ml with liraglutide 3.6mg per ml (brand name Xultophy) for the treatment of type 2 diabetes mellitus 1.4 Adapalene 1mg/gram with benzoyl peroxide 25mg/gram gel (brand name Epiduo) for the treatment of acne 1.5 Docusate sodium oral solution sugar free 50mg/5mL (generic only) Colecalciferol solution (Thorens brand) 25,000 units in 2.5 ml oral solution 2 Additional strengths of products already listed 2.1 Buprenorphine patch 20mcg/hour for the treatment of pain 2.2 Oxycodone m/r tablet 30mg for moderate-severe pain 2.3 Beclometasone 200mcg/dose with formoterol 6mcg/dose metered dose inhaler and dry powder inhaler (brand names Fostair and Fostair NEXThaler) 2.4 Levothyroxine tablets 75mcg (generic only) 2.5 Estradiol with dydrogesterone tablets 0.5mg/2.5mg (brand name Femoston-conti) - Items to be removed from the Prescribed List
3.1 Hypromellose preservative-free eye drops 0.32% as lower cost alternatives are available. 3.2 Betamethasone valerate 0.1% with neomycin 0.5% cream and ointment following discontinuation of Betnovate N brand 3.3 The Committee supported the removal of Erythromycin 40 mg, zinc acetate 12 mg/mL (brand name Zineryt) for the treatment subject to wider consultation due to the extensive use of this product at present 4 Other amendments to the Prescribed List 4.1 Buprenorphine patch 5mcg, 10mcg, 20mcg to be reimbursed for both branded and generic products 4.2 Oral contraceptives to be reimbursed for both branded and generic products currently included in the Prescribed List 4.3 Glycopyrronium bromide entry to be amended entries in the Prescribed List to specify strength as 55mcg per dose not 50mcg The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund. |